ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1847

Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis

Elizabeth Volkmann1, Donald Tashkin2, Mei Leng2, Grace Kim2, Jonathan Goldin2 and Michael Roth2, 1Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2021

Keywords: interstitial lung disease, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Esophageal dysmotility is a common feature of systemic sclerosis (SSc) and aspiration of gastric contents may serve as an inciting and/or exacerbating factor in the pathogenesis of interstitial lung disease (ILD). The present study aimed to: (1) determine whether the severity of gastroesophageal reflux predicts progression of SSc-ILD and (2) evaluate whether proton pump inhibitors (PPI) moderate the relationship between reflux severity and ILD progression as defined both radiographically and physiologically.

Methods: The UCLA SCTC GIT 2.0 was used to assess the severity of reflux in participants of Scleroderma Lung Study (SLS) II (Tashkin et al. Lancet Resp Med 2016). SLS II compared 24 months of mycophenolate versus 12 months cyclophosphamide followed by 12 months of placebo in patients with active SSc-ILD. A multivariable linear regression analysis was used to evaluate the relationship between baseline reflux scores and change in quantitative extent of radiographic ILD (QILD) and fibrosis (QLF) in the whole lung at 24 months. A joint model was created to evaluate the relationship between baseline reflux scores and the course of the forced vital capacity (FVC)%-predicted measured every 3 months over 24 months. All models controlled for treatment arm and baseline ILD severity, and tested whether PPI use was associated with ILD progression.

Results: 141 of the 142 SLS II participants had reflux scores at baseline and the mean score was 0.57, indicating moderate severity. There were no significant correlations between baseline reflux score and FVC%-predicted, QLF, QILD, disease duration, skin score, gender or the presence of diffuse cutaneous disease. Among participants with follow up HRCT scans (N=96), increased severity of reflux was significantly associated with increased QLF (Table 1) and QILD (Table 2) scores at 24 months. However, increased severity of reflux was not significantly associated with the course of the FVC%-predicted (N=130; Table 3). 112 (78.9%) of SLS II participants were taking a PPI at baseline; PPI users had higher reflux scores than non-users (P= < 0.0001). PPI use was not significantly associated with progression of ILD in any of the models.

Conclusion: Among patients receiving treatment for SSc-ILD, increased severity of gastroesophageal reflux symptoms was associated with ILD progression, based on worsening extent of radiographic fibrosis and total ILD, but not with the course of the FVC. PPI use was not associated with progression of ILD, suggesting that aspiration of non-acid gastric contents may play a role in perpetuating inflammation and fibrosis in SSc-ILD. Future studies are needed to assess whether other reflux treatments (e.g., pro-motility agents) moderate the relationship between reflux severity and ILD progression in SSc.


Disclosures: E. Volkmann, Boehringer Ingelheim, 2, 6, Corbus, 5, Forbius, 5, Kadmon, 5; D. Tashkin, None; M. Leng, None; G. Kim, None; J. Goldin, None; M. Roth, Genentech/Roche, 5.

To cite this abstract in AMA style:

Volkmann E, Tashkin D, Leng M, Kim G, Goldin J, Roth M. Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/severity-of-gastroesophageal-reflux-but-not-the-use-of-proton-pump-inhibitors-is-associated-with-radiographic-progression-of-interstitial-lung-disease-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/severity-of-gastroesophageal-reflux-but-not-the-use-of-proton-pump-inhibitors-is-associated-with-radiographic-progression-of-interstitial-lung-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology